Top As­traZeneca I/O ex­ec jumps to Seat­tle Ge­net­ics as first CCO; Wood­ford fund down­grad­ed as woes mount

→ Seat­tle Ge­net­ics has raid­ed the top ranks at As­traZeneca for its first chief com­mer­cial of­fi­cer. Robin Tay­lor is mak­ing the leap from the UK phar­ma gi­ant, where he’s been for just 7 months as the fran­chise head for im­muno-on­col­o­gy. As­traZeneca has been la­bor­ing at widen­ing the mar­ket pen­e­tra­tion for its PD-L1 Imfinzi. Tay­lor jumped to As­traZeneca from Genen­tech, where he led the can­cer im­munother­a­py fran­chise. Tay­lor had been at Genen­tech for close to 18 years, start­ing with a brief stint there as a sum­mer in­tern. He worked on some of the com­pa­ny’s top fran­chis­es, in­clud­ing Avastin, Her­ceptin and Tecen­triq.

Unlock this article instantly by becoming a free subscriber.

You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.

SIGN UP LOG IN BECOME A PREMIUM SUBSCRIBER